Puma Biotechnology | PBYI - Selling And Administration Expenses

Stock Price
6.62
Daily Change
0.01 0.12%
Monthly
5.38%
Yearly
137.20%
Q1 Forecast
5.65

Puma Biotechnology reported $16.82M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Incyte USD 390.41M 61.33M Dec/2025
MacroGenics USD 9.9M 600K Sep/2025
Moderna USD 268M 38M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Takeda JPY 282.78B 29.23B Dec/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025